(Q60193091)
Statements
The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer (English)
Adams M
Navabi H
Croston D
Coleman S
Jasani B
scientific article published on 01 March 2005